BridgeBio Oncology: The KRAS Opportunity Hidden In The SelloffSeeking Alpha · Oct 19, 2026
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 12, 2026
BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Receives Consensus Rating of “Moderate Buy” from AnalystsDefense World · Oct 8, 2026
Brokerages Set BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Price Target at $22.88Defense World · Sep 16, 2026
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant CancersGlobeNewsWire · Sep 8, 2026
BBOT to Participate in Upcoming Investor Healthcare ConferencesGlobeNewsWire · Sep 1, 2026BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.57 | -$0.71 | Miss |
| May 12, 2026 | -$0.51 | -$0.48 | Beat |
| Mar 5, 2026 | -$0.63 | -$0.49 | Beat |
| Nov 12, 2025 | -$0.38 | -$1.03 | Miss |
| Aug 1, 2025 | -$42.45 | -$50.35 | Miss |
| May 15, 2025 | – | -$52.15 |